ZELBORAF (vemurafenib) - association with liver problems

Hoffmann-La Roche Limited (Roche Canada), in consultation with Health Canada, would like to inform you of important new safety information regarding the risk of Drug Induced Liver Injury (DILI) reported with ZELBORAF. ZELBORAF is indicated as a monotherapy for the treatment of BRAF V600 mutation-positive unresectable or metastatic melanoma. A validated test is required to identify BRAF V600 mutation status. Read more here.